Cancer Drug Costs Up In Part D With Expanded Use And Price Growth
Medicare 'Dashboard' spotlights costliest drugs in Part D and Part B programs to help inform public debate around controlling spending increases.
You may also be interested in...
Why Is Congress Targeting These Six Medicines In Drug Price Hearing?
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
Medicaid ‘Price Verification’ Audit Proposal Aims To Promote Cell, Gene Therapy Rebate Concessions
CMS proposed rule impact may be ‘modest’ but is framed as ensuring patient access to cutting edge treatments by helping to control Medicaid spending. Biden administration initiative also aims to address misclassification of brand drugs, duplicative 340B discounts, and PBM spread pricing.
Medicare Unlikely To Embrace Cost Effectiveness In Early Price Negotiations – ICER’s Pearson
The government’s rush to stand up the negotiation program by the fall likely means an approach to cost effectiveness will be left out of at least the first cycle. But it could be incorporated over time.